NO782326L - Nye prostaglandinderivater. - Google Patents

Nye prostaglandinderivater.

Info

Publication number
NO782326L
NO782326L NO782326A NO782326A NO782326L NO 782326 L NO782326 L NO 782326L NO 782326 A NO782326 A NO 782326A NO 782326 A NO782326 A NO 782326A NO 782326 L NO782326 L NO 782326L
Authority
NO
Norway
Prior art keywords
hydrogen
formula
nat
hydroxy
acid
Prior art date
Application number
NO782326A
Other languages
English (en)
Norwegian (no)
Inventor
George William Holland
Perry Rosen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/813,068 external-priority patent/US4163016A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO782326L publication Critical patent/NO782326L/no

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO782326A 1977-07-05 1978-07-04 Nye prostaglandinderivater. NO782326L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/813,068 US4163016A (en) 1977-07-05 1977-07-05 16-Substituted prostaglandins

Publications (1)

Publication Number Publication Date
NO782326L true NO782326L (no) 1979-01-08

Family

ID=25211375

Family Applications (1)

Application Number Title Priority Date Filing Date
NO782326A NO782326L (no) 1977-07-05 1978-07-04 Nye prostaglandinderivater.

Country Status (12)

Country Link
DK (1) DK302878A (es)
ES (1) ES471416A1 (es)
FI (1) FI782166A (es)
GR (1) GR72118B (es)
IL (1) IL55042A0 (es)
IT (1) IT1096959B (es)
MC (1) MC1196A1 (es)
NO (1) NO782326L (es)
NZ (1) NZ187726A (es)
PH (1) PH14153A (es)
PT (1) PT68249A (es)
ZA (1) ZA783704B (es)

Also Published As

Publication number Publication date
MC1196A1 (fr) 1979-03-19
GR72118B (es) 1983-09-15
NZ187726A (en) 1981-03-16
ZA783704B (en) 1979-07-25
IT1096959B (it) 1985-08-26
ES471416A1 (es) 1979-10-01
DK302878A (da) 1979-01-06
IL55042A0 (en) 1978-08-31
PH14153A (en) 1981-03-06
IT7825366A0 (it) 1978-07-05
PT68249A (en) 1978-08-01
FI782166A (fi) 1979-01-06

Similar Documents

Publication Publication Date Title
US4033989A (en) 9-Deoxy-PGF2 Analogs
JPS5929193B2 (ja) 4,4,5,5−テトラデヒドロpgf1
US4060534A (en) 9-Deoxy-9-methylene-PGF compounds
US4087435A (en) 8-Aza-9-dioxothiaprostanoic acids
FI70009C (fi) Foerfarande foer framstaellning av nya 1,5-disubstituerad-2-pyrrolidonfoereningar vilka har prostaglandinliknande biologiska egenskaper
US4154950A (en) 15-Epi-15-methyl-16-phenoxy-PGE compounds
EP0019440B1 (en) Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them
US4212993A (en) 16-Substituted prostaglandins
US4219483A (en) 4-Pyrone prostaglandin antagonists
CA1091664A (en) Prostaglandin derivatives
RO109332B1 (ro) Procedeu pentru prepararea unor analogi ai 13,14-dihidroderivatilor de prostaglandina
US3845115A (en) 15-lower alkoxy pgf compounds
NO782326L (no) Nye prostaglandinderivater.
US4306078A (en) 16-Substituted prostaglandins
US4204074A (en) 16-Substituted prostaglandins
US4091015A (en) 15-Substituted prostanoic acids
US4232173A (en) 15-Sulfonamidoprostaglandin derivatives
US3974195A (en) 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
US4404372A (en) 15-Substituted-ω-pentanorprostaglandin derivatives
US4260818A (en) 16-Substituted prostaglandins
FR2515642A1 (fr) Nouvelles (11r)-11-deoxy-11-alkyl-6-oxo-prostaglandines et compositions pharmaceutiques les contenant
US4029693A (en) 2A,2B-Dihomo-11-deoxy-17(substituted phenyl)-18,19,20-trinor-PGE2 compounds and their corresponding esters
US4292444A (en) Sulfonyl prostaglandin carboxamide derivatives
JPH08217672A (ja) キサントン誘導体を含有する抗ヘリコバクター・ピロリ薬
CA1041012A (en) Method of reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammotory drugs and compositions therefor